• About
  • Services
  • Clients
  • Client Media
    • Client News
    • Client Videos
    • CEO Insights
  • PCG Research
  • PCG Digital
    • PCG Digital Tech Watch
    • PCG Digital Biotech Watch
  • Contact
  • follow:

  • 9 May

    Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

    Initial data from open label Phase 2a study expected in late 2022 IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative… Read More..

    Share this:
  • 26 Apr

    Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

    Proof-of-concept studies go beyond typical DNA data storage projects to ensure high-fidelity data recovery within an automated synthetic biology workflow SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept demonstrations showing that… Read More..

    Share this:
  • 21 Apr

    Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

    25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of… Read More..

    Share this:
« Previous 1 … 3 4 5 6 7 … 39 Next »
  • PCG Advisory GroupFollow

    PCG Advisory Group
    PCGAdvisoryPCG Advisory Group@PCGAdvisory·
    30 Jun

    Soligenix (NASDAQ:SNGX) Continues on Its Track by Making Progress on Milestones
    https://t.co/aaBZixC993

    Reply on Twitter 1542569911205101568Retweet on Twitter 15425699112051015689Like on Twitter 154256991120510156891Twitter 1542569911205101568
    PCGAdvisoryPCG Advisory Group@PCGAdvisory·
    28 Jun

    Asensus Surgical: (NYSE American: $ASXC) Key commercial and regulatory milestones expected during the second half of 2022
    #surgicalrobotics #roboticsurgicalsystem #investors #DayTrading #investment #smallcaps
    Read our disclosures at https://t.co/RU1aW7XYbc
    https://t.co/Xxflcrbgiw

    Reply on Twitter 1541839295195058181Retweet on Twitter 1541839295195058181Like on Twitter 15418392951950581811Twitter 1541839295195058181
    PCGAdvisoryPCG Advisory Group@PCGAdvisory·
    28 Jun

    Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis https://t.co/xjswtZ8Sk8 #biopharma #stocks #stockstowatch #stockmarket #investors #daytrader #investing #SNGX $SNGX Read our disclosures at https://t.co/RU1aW7XYbc

    Reply on Twitter 1541802097477390338Retweet on Twitter 15418020974773903381Like on Twitter 1541802097477390338Twitter 1541802097477390338
    Load More...
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client Media
      • Client News
      • Client Videos
      • CEO Insights
    • PCG Research
    • PCG Digital
      • PCG Digital Tech Watch
      • PCG Digital Biotech Watch
    • Contact